Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.54 |
| ▸ | PTP4A3 | O75365 | 1/20 | 0.36 |
| ▸ | PTP4A2 | Q12974 | 1/20 | 0.36 |
| ▸ | PTP4A1 | Q93096 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.32 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.32 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22859936 | 0.77 | GSK3B (0.46) | GSK3BALDH1A1MAPTPKMNPSR1 | |
| Ammonia Solution, Strong SCHEMBL15716761 | 0.76 | GSK3B (0.51) | GSK3BPTP4A3PTP4A2PTP4A1ALDH1A1 | |
| SCHEMBL15716938 | 0.76 | GSK3B (0.51) | GSK3BPTP4A3PTP4A2PTP4A1ALDH1A1 | |
| SCHEMBL13606460 | 0.75 | GSK3B (0.41) | GSK3BPTP4A3PTP4A2PTP4A1ALDH1A1 | |
| SCHEMBL31484430 | 0.73 | KDM4E (0.50) | GSK3BPTP4A3PTP4A2PTP4A1ALDH1A1 | |
| SCHEMBL17779584 | 0.72 | POLB (0.36) | ALDH1A1GLAMAPTPKMNPSR1 | |
| SCHEMBL4494878 | 0.72 | GSK3B (0.74) | GSK3BPTP4A3PTP4A2PTP4A1ALDH1A1 | |
| SCHEMBL17321357 | 0.69 | GSK3B (0.37) | GSK3BALDH1A1GLADAOERCC1 | |
| SCHEMBL5240090 | 0.67 | GSK3B (0.45) | GSK3BPTP4A3PTP4A2PTP4A1ALDH1A1 | |
| SCHEMBL22301768 | 0.67 | BRD9 (0.35) | MAPTPKMNPSR1RXFP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275570-A1 | SUBSTITUTED HETEROCYCLES AND THEIR USE AS CHK1, PDK1 AND PAK INHIBITORS | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| EP-1869052-A1 | SUBSTITUTED HETEROCYCLES AND THEIR USE AS CHK1, PDK1 AND PAK INHIBITORS | AstraZeneca AB (SE) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006106326-A1 | SUBSTITUTED HETEROCYCLES AND THEIR USE AS CHK1, PDK1 AND PAK INHIBITORS | ASTRAZENECA AB (SE) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275570-A1 | SUBSTITUTED HETEROCYCLES AND THEIR USE AS CHK1, PDK1 AND PAK INHIBITORS | CHEK1, PDK1, CHEK2 | GSK3B 256/4885PTP4A3 3405/4885PTP4A2 3291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.